Study of effectiveness of Maharishi Amrit Kalash on Breast Cancer as adjunct therapy along with Docetaxil and Epirubicine chemotherapy.

Maharishi Ayurveda Products Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients who are willing to participate in the study.
•2. Women between age18 and 70 years, with histopathologically confirmed breast carcinoma of maximum diameter equal to 2.1 cm or above in whom neoadjuvant chemotherapy is planned.
•3.Patients with skin involvement with fixed nodal metastasis will also be included.
•4.Patients signed written informed consent.
•5.Patients with normal liver and renal function test and normal ECG and echocardiogram.

•1. Patients unwilling to participate.
•2. Pregnant and lactating women.
•3. Patients with concomitant severe heart, liver or renal diseases.
•4. Patients with type one diabetes or uncontrolled type two diabetes with complications and/or on Insulin.
•5.Patients deemed unfit to received chemotherapy due to poor general health

发起方

Maharishi Ayurveda Products Pvt Ltd